Table 1.
Baseline characteristics of the patients
| Placebo | 150 mg irbesartan | 300 mg irbesartan | |
|---|---|---|---|
| n | 17 | 16 | 17 |
| Sex (M/F) | 13/4 | 15/1 | 14/3 |
| Age (years) | 60 (54–66) | 58 (53–67) | 55 (50–62) |
| Smokers (%) | 6 (35) | 9 (56) | 5 (29) |
| Weight (kg) | 84.8 ± 14.1 | 91.8 ± 9.5 | 87.5 ± 14.7 |
| BMI (kg/m2) | 27.2 (26.8–29.6) | 28.4 (27.1–30.4) | 29.6 (25.1–31.4) |
| Known diabetes duration (years) | 6 (3–13) | 8.5 (6–12) | 9 (4–12) |
| Systolic blood pressure (mmHg) | 155 ± 15 | 156 ± 15 | 156 ± 19 |
| Diastolic blood pressure (mmHg) | 88 ± 7 | 91 ± 11 | 89 ± 9 |
| Urinary albumin excretion (μg/min) | 63 (39–81) | 45 (25.5–85.5) | 51 (39–109) |
| GFR (mL/min per 1.73 m2) | 107.4 ± 27.7 | 115.6 ± 20.5 | 116.6 ± 21.2 |
| HbA1c (%) | 7.1 ± 1.5 | 6.9 ± 1.3 | 6.8 ± 1.5 |
| Hemoglobin (mmol/L) | 8.9 (8.6–9.2) | 9.2 (9.0–9.6) | 9.1 (8.4–9.3) |
| Cholesterol (mmol/L) | 5.56 (5.04–5.90) | 5.61 (5.02–6.31) | 5.59 (5.04–5.92) |
| LDL cholesterol (mmol/L) | 3.21 (3.08–3.57) | 3.44 (2.48–3.67) | 3.18 (2.77–3.70) |
| HDL cholesterol (mmol/L) | 1.06 (0.96–1.22) | 1.03 (0.83–1.32) | 1.11 (1.01–1.40) |
| Triglycerides (mmol/L) | 1.78 (1.46–2.86) | 2.04 (1.46–3.78) | 2.31 (1.24–3.21) |
| Serum creatinine (μmol/L) | 97 (88–106) | 97 (88–102) | 88 (80–97) |
| 8-oxodG (nmol/mmol creatinine) | 2.10 (1.76–3.05) | 1.92 (1.47–2.20) | 2.59 (1.64–3.14) |
| 8-oxoGuo (nmol/mmol creatinine) | 3.63 (2.70–4.38) | 2.86 (2.45–3.84) | 4.01 (2.99–5.08) |
Data are means ± SD or median (interquartile range) unless otherwise indicated. NS between all treatment groups.